TIDMMXCT TIDMTTM

RNS Number : 5037L

MaxCyte, Inc.

16 May 2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, MD, May 16, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on May 10, 2022, the Compensation Committee of MaxCyte's Board of Directors granted stock options to purchase an aggregate of 73,700 shares of MaxCyte's common stock to six (6) newly hired employees. The stock options were granted as material inducements to employment with MaxCyte in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the MaxCyte, Inc. 2021 Inducement Plan (the "2021 Inducement Plan").

The stock options have a ten-year term and an exercise price of $4.81 per share, which is equal to the closing price of MaxCyte's common stock on May 10, 2022. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with MaxCyte on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an award agreement covering the grants.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)and VLx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

 
 US IR Adviser                                    +1 415-937-5400 
  Gilmartin Group                                  ir@maxcyte.com 
  David Deuchler, CFA 
 Nominated Adviser and Joint Corporate Broker 
  Panmure Gordon 
  Emma Earl / Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                  +44 (0)20 7886 2500 
                                                  +44 (0)203 709 5700 
   UK IR Adviser                                   maxcyte@consilium-comms.com 
   Consilium Strategic Communications 
   Mary-Jane Elliott 
   Chris Welsh 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCAJMATMTMBBTT

(END) Dow Jones Newswires

May 16, 2022 02:00 ET (06:00 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Maxcyte Charts.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Maxcyte Charts.